Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jay Tanna"'
Autor:
Michael D. Keller, Patrick J. Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C. Dvorak, Michael R. Verneris, Donald B. Kohn, Sung-Yun Pai, Blachy J. Dávila Saldaña, Benjamin Hanisch, Troy C. Quigg, Roberta H. Adams, Ann Dahlberg, Shanmuganathan Chandrakasan, Hasibul Hasan, Jemily Malvar, Mariah A. Jensen-Wachspress, Christopher A. Lazarski, Gelina Sani, John M. Idso, Haili Lang, Pamela Chansky, Chase D. McCann, Jay Tanna, Allistair A. Abraham, Jennifer L. Webb, Abeer Shibli, Amy K. Keating, Prakash Satwani, Pawel Muranski, Erin Hall, Michael J. Eckrich, Evan Shereck, Holly Miller, Ewelina Mamcarz, Rajni Agarwal, Satiro N. De Oliveira, Mark T. Vander Lugt, Christen L. Ebens, Victor M. Aquino, Jeffrey J. Bednarski, Julia Chu, Suhag Parikh, Jennifer Whangbo, Michail Lionakis, Elias T. Zambidis, Elizabeth Gourdine, Catherine M. Bollard, Michael A. Pulsipher
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter stud
Externí odkaz:
https://doaj.org/article/fcdca2f7424c452f994b7e545a14509b
Autor:
Michael D. Keller, Stefan A. Schattgen, Shanmuganathan Chandrakasan, E. Kaitlynn Allen, Mariah A. Jensen-Wachspress, Christopher A. Lazarski, Muna Qayed, Haili Lang, Patrick J. Hanley, Jay Tanna, Sung-Yun Pai, Suhag Parikh, Seth I. Berger, Stephen Gottschalk, Michael A. Pulsipher, Paul G. Thomas, Catherine M. Bollard
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare adverse events have been desc
Externí odkaz:
https://doaj.org/article/2d98f25b1b53444d849e04310e6b7692
Publikováno v:
IEEE Sensors Journal. 23:11428-11436
Autor:
Minelys M Alicea Marrero, Sandhya Vijapurapu, Kathryn Bushnell, Jennifer Webb, Mrs. Radha Rohatgi, Allyson Flores, David Leitenberg, Alexa Yarish, Jay Tanna, Patrick J. Hanley, Christina Wiedl, Keri Toner, Allistair Abraham, Blachy J. Davila Saldana, Michael A Pulsipher, David Jacobsohn, Anant Vatsayan
Publikováno v:
Transplantation and Cellular Therapy. 29:S238-S239
Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease
Autor:
Hannah Kinoshita, Mamatha Mandava, Mariah Jensen-Wachspress, Haili Lang, Elisabeth Joy, Jay Tanna, Chase D. McCann, Samuel O’Brien, Sianna Burnett, Abeer Shibli, Fahmida Hoq, Monica Bhatia, Patrick J. Hanley, Blachy Dávila Saldaña, Kris M. Mahadeo, Catherine M. Bollard, Michael D. Keller, Allistair Abraham
Publikováno v:
Blood advances.
Hematopoietic stem cell transplantation (HSCT) is being increasingly used as a curative approach for sickle cell disease (SCD). With the risk of graft-versus-host disease (GVHD), especially in the human leukocyte antigen−mismatched donors, intense
Autor:
Jay Tanna, Patrick J. Hanley, Jonathan H. Esensten, Nan Zhang, Julie Annis, Catherine Lindgren, Ashley S. Leinbach
Publikováno v:
Cytotherapy
``Cellular therapies first emerged as specialized therapies only available at a few “boutique” centers worldwide. To ensure broad access to these investigational therapies—regardless of geography, demographics and other factors—more and more
Autor:
Hannah Kinoshita, Kenneth R. Cooke, Melanie Grant, Maja Stanojevic, C. Russell Cruz, Michael Keller, Maria Fernanda Fortiz, Fahmida Hoq, Haili Lang, A. John Barrett, Hua Liang, Jay Tanna, Nan Zhang, Abeer Shibli, Anushree Datar, Kenneth Fulton, Divyesh Kukadiya, Anqing Zhang, Kirsten M. Williams, Hema Dave, Jeffrey S. Dome, David Jacobsohn, Patrick J. Hanley, Richard J. Jones, Catherine M. Bollard
Publikováno v:
Blood advances. 6(8)
Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of
Autor:
Eugene Hwang, Fernanda Fortiz, Russell Cruz, Ashley Geiger, Melanie Grant, Haili Lang, Abeer Shibli, Sianna Burnett, Chris Lazarski, Jay Tanna, Chase McCann, Fahmida Hoq, Patrick Hanley, Lindsay Kilburn, Brian Rood, Roger Packer, Catherine Bollard
Publikováno v:
Neuro-Oncology. 24:i85-i86
BACKGROUND: The ReMIND trial hypothesizes that autologous T-cells specific for three tumor-associated antigens (TAA) -WT1, PRAME, and survivin- will be safe and elicit anti-tumor immunity in pediatric patients with CNS cancer. METHODS: Patients (n=25
Autor:
Michael D. Keller, Patrick J. Hanley, Jay Tanna, Mariah Jensen-Wachspress, Haili Lang, Paibel Aguayo-Hiraldo, Troy C. Quigg, Michael R. Verneris, Suhag Parikh, Christopher C. Dvorak, Prakash Satwani, Blachy Davila-Saldana, Jeffrey J. Bednarski II, Sung-Yun Pai, Jennifer Whangbo, Shanmuganathan Chandrakasan, Evan Shereck, Rajni Agarwal, Victor Aquino, Christen L. Ebens, Ann Dahlberg, Liz Gourdine, Catherine M. Bollard, Mike A. Pulsipher
Publikováno v:
Transplantation and Cellular Therapy. 28:S1-S2
Autor:
Shubhangi A Desai, Aliabbas A. Husain, Dhananjay Raje, Shailendra Mundhada, Jay Tanna, Rajpal S. Kashyap, Madhavi Deshmukh, Bishwadeep Singha, Amit R. Nayak
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) virus has emerged as public health emergency affecting 206 countries worldwide. India is second highest currently worst effected by Covid 19 pandemic with cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8ce16aed45b57ff2e5e1e58039324b
https://doi.org/10.1101/2021.05.11.21256719
https://doi.org/10.1101/2021.05.11.21256719